Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 76.1%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 39,700 shares, a drop of 76.1% from the February 29th total of 166,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 212,600 shares, the short-interest ratio is currently 0.2 days.

Coeptis Therapeutics Stock Performance

Shares of Coeptis Therapeutics stock remained flat at $0.30 during trading on Thursday. The stock had a trading volume of 157,269 shares, compared to its average volume of 219,299. The stock has a market cap of $10.14 million, a price-to-earnings ratio of -0.35 and a beta of -0.79. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.03. Coeptis Therapeutics has a 1 year low of $0.29 and a 1 year high of $2.19. The firm’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.83.

Institutional Investors Weigh In On Coeptis Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new stake in Coeptis Therapeutics during the first quarter valued at about $57,000. Morgan Stanley bought a new stake in Coeptis Therapeutics during the fourth quarter valued at about $64,000. Ionic Capital Management LLC bought a new stake in Coeptis Therapeutics during the second quarter valued at about $70,000. Mint Tower Capital Management B.V. bought a new stake in Coeptis Therapeutics during the fourth quarter valued at about $35,000. Finally, Shaolin Capital Management LLC bought a new stake in Coeptis Therapeutics during the second quarter valued at about $70,000. Institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.